Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients

Oncotarget

Volumn 7, Issue 12, 2016, Pages 14083-14094

  Abd Al Samid, May ^a,b   Chaudhary, Belal ^a   Khaled, Yazan S ^c   Ammori, Basil J ^c   Elkord, Eyad ^a,b,c  

^a UNIVERSITY OF SALFORD   (United Kingdom)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

FoxP3; GARP LAP; Helios; Markers; Regulatory T cells

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN A REPETITION PREDOMINANT PROTEIN; HELIOS PROTEIN; INTERLEUKIN 10; LATENCY ASSOCIATED PEPTIDE; TRANSCRIPTION FACTOR FOXP3; TUMOR MARKER; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; HEAT SHOCK COGNATE PROTEIN 70; HSPA8 PROTEIN, HUMAN; IKAROS TRANSCRIPTION FACTOR; IKZF2 PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; LRRC32 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CD4+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIVER METASTASIS; MALE; PANCREAS CANCER; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; CANCER GRADING; CASE CONTROL STUDY; COLORECTAL TUMOR; FOLLOW UP; IMMUNOLOGY; LIVER TUMOR; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; HSC70 HEAT-SHOCK PROTEINS; HUMANS; IKAROS TRANSCRIPTION FACTOR; INTERLEUKIN-10; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84971667607     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7334     Document Type: Article

References (37)

1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008; 133: 775-787.
2. Elkord E, AlcantarOrozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE. T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther. 2010; 10: 1573-1586.
3. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014; 27: 1-7.
4. Chaudhary B, Abd Al Samid M, alRamadi BK, Elkord E. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opin Biol Ther. 2014; 14: 931-945.
5. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006; 12: 5423-5434.
6. Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of GARP(+)CTLA4(+)Foxp3(+) T regulatory cells and myeloidderived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013; 73: 2435-2444.
7. PedrozaGonzalez A, Verhoef C, Ijzermans JN, Peppelenbosch MP, Kwekkeboom J, Verheij J, Janssen HL, Sprengers D. Activated tumorinfiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology. 2013; 57: 183-194.
8. Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, Smyth MJ. Transient Foxp3(+) regulatory Tcell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunol Cell Biol. 2013; 91: 105-114.
9. Singer BD, King LS, D'Alessio FR. Regulatory T cells as immunotherapy. Front Immunol. 2014; 5: 46.
10. Wolf D, Wolf AM. CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies-Immunooncology Advances Clinical Cancer Research. Clin Cancer Res. 2015; 21: 2657-2659.
11. Dong S, Maiella S, Xhaard A, Pang Y, Wenandy L, Larghero J, Becavin C, Benecke A, Bianchi E, Socie G, Rogge L. Multiparameter singlecell profiling of human CD4+FOXP3+ regulatory Tcell populations in homeostatic conditions and during graftversushost disease. Blood. 2013; 122: 1802-1812.
12. Duhen T, Duhen R, Lanzavecchia A, Sallusto F, Campbell DJ. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood. 2012; 119: 4430-4440.
13. Gratz IK, Campbell DJ. Organspecific and memory treg cells: specificity, development, function, and maintenance. Front Immunol. 2014; 5: 333.
14. Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol. 2014; 14: 154-165.
15. Mason GM, Lowe K, Melchiotti R, Ellis R, de Rinaldis E, Peakman M, Heck S, Lombardi G, Tree TI. Phenotypic Complexity of the Human Regulatory T Cell Compartment Revealed by Mass Cytometry. J Immunol. 2015; 195: 2030-2037.
16. Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, Scheffold A, Shevach EM, Staats J, et al. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother. 2015; 64: 1271-1286.
17. Liston A, Piccirillo CA. Developmental plasticity of murine and human Foxp3(+) regulatory T cells. Adv Immunol. 2013; 119: 85-106.
18. Sebastian M, LopezOcasio M, Metidji A, Rieder SA, Shevach EM, Thornton AM. Helios Controls a Limited Subset of Regulatory T Cell Functions. J Immunol. 2016; 196: 144-155.
19. Takatori H, Kawashima H, Matsuki A, Meguro K, Tanaka S, Iwamoto T, Sanayama Y, Nishikawa N, Tamachi T, Ikeda K, Suto A, Suzuki K, Kagami S, et al. Helios Enhances Treg Cell Function in Cooperation With FoxP3. Arthritis Rheumatol. 2015; 67: 1491-1502.
20. Elkord E, AlRamadi BK. Helios expression in FoxP3(+) T regulatory cells. Expert Opin Biol Ther. 2012; 12: 1423-1425.
21. Zabransky DJ, Nirschl CJ, Durham NM, Park BV, Ceccato CM, Bruno TC, Tam AJ, Getnet D, Drake CG. Phenotypic and functional properties of Helios+ regulatory T cells. PLoS One. 2012; 7: e34547.
22. Rifkin DB. Latent transforming growth factorbeta (TGFbeta) binding proteins: orchestrators of TGFbeta availability. J Biol Chem. 2005; 280: 7409-7412.
23. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP (LRRC32) is essential for the surface expression of latent TGFbeta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A. 2009; 106: 13445-13450.
24. Sun J, Tang DN, Fu T, Sharma P. Identification of human regulatory T cells in the setting of Tcell activation and anti-CTLA-4 immunotherapy on the basis of expression of latencyassociated peptide. Cancer Discov. 2012; 2: 122-130.
25. Tran DQ, Andersson J, Hardwick D, Bebris L, Illei GG, Shevach EM. Selective expression of latency-associated peptide (LAP) and IL1receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood. 2009; 113: 5125-5133.
26. Elkord E, Abd Al Samid M, Chaudhary B. Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP. Oncotarget. 2015; 6: 20026-20036. doi: 10.18632/oncotarget.4771.
27. Elkord E, Sharma S, Burt DJ, Hawkins RE. Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma coexpress Helios, indicating they could be derived from natural but not induced Tregs. Clin Immunol. 2011; 140: 218-222.
28. Gandhi R, Farez MF, Wang Y, Kozoriz D, Quintana FJ, Weiner HL. Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset. J Immunol. 2010; 184: 4620-4624.
29. Mahalingam J, Lin YC, Chiang JM, Su PJ, Fang JH, Chu YY, Huang CT, Chiu CT, Lin CY. LAP+CD4+ T cells are suppressors accumulated in the tumor sites and associated with the progression of colorectal cancer. Clin Cancer Res. 2012; 18: 5224-5233.
30. Mahalingam J, Lin CY, Chiang JM, Su PJ, Chu YY, Lai HY, Fang JH, Huang CT, Lin YC. CD4(+) T cells expressing latency-associated peptide and Foxp3 are an activated subgroup of regulatory T cells enriched in patients with colorectal cancer. PLoS One. 2014; 9: e108554.
31. Scurr M, Ladell K, Besneux M, Christian A, Hockey T, Smart K, Bridgeman H, Hargest R, Phillips S, Davies M, Price D, Gallimore A, Godkin A. Highly prevalent colorectal cancerinfiltrating LAP(+) Foxp3(-) T cells exhibit more potent immunosuppressive activity than Foxp3(+) regulatory T cells. Mucosal Immunol. 2014; 7: 428-439.
32. Schuler PJ, Harasymczuk M, Schilling B, Saze Z, Strauss L, Lang S, Johnson JT, Whiteside TL. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res. 2013; 19: 6585-6596.
33. Govindaraj C, ScalzoInguanti K, Madondo M, Hallo J, Flanagan K, Quinn M, Plebanski M. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clin Immunol. 2013; 149: 97-110.
34. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW. Helios expression is a marker of T cell activation and proliferation. PLoS One. 2011; 6: e24226.
35. ProbstKepper M, Buer J. FOXP3 and GARP (LRRC32): the master and its minion. Biol Direct. 2010; 5: 8.
36. Alexander T, Sattler A, Templin L, Kohler S, Gross C, Meisel A, Sawitzki B, Burmester GR, Arnold R, Radbruch A, Thiel A, Hiepe F. Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis. 2013; 72: 1549-1558.
37. Cuende J, Lienart S, Dedobbeleer O, van der Woning B, De Boeck G, Stockis J, Huygens C, Colau D, Somja J, Delvenne P, Hannon M, Baron F, Dumoutier L, et al. Monoclonal antibodies against GARP/TGF-beta1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Sci Transl Med. 2015; 7:284ra256.